File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia

TitleBest practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Authors
KeywordsInflammatory bowel disease
Crohn disease
Colitis
ulcerative
Infliximab
Issue Date2019
PublisherKorean Association for the Study of Intestinal Diseases. The Journal's web site is located at http://www.irjournal.org/
Citation
Intestinal Research, 2019, v. 17 n. 3, p. 285-310 How to Cite?
AbstractThe Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
DescriptionOn behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis
Persistent Identifierhttp://hdl.handle.net/10722/287157
ISSN
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorOoi, CJ-
dc.contributor.authorHilmi, I-
dc.contributor.authorBanerjee, R-
dc.contributor.authorChuah, SW-
dc.contributor.authorNg, SC-
dc.contributor.authorWei, SC-
dc.contributor.authorMakharia, GK-
dc.contributor.authorPisespongsa, P-
dc.contributor.authorChen, MH-
dc.contributor.authorRen, ZH-
dc.contributor.authorYe, BD-
dc.contributor.authorPark, DI-
dc.contributor.authorLing, KL-
dc.contributor.authorOng, D-
dc.contributor.authorAhuja, V-
dc.contributor.authorGoh, KL-
dc.contributor.authorSollano, J-
dc.contributor.authorLim, WC-
dc.contributor.authorLeung, WK-
dc.contributor.authorAli, RAR-
dc.contributor.authorWu, DC-
dc.contributor.authorOng, E-
dc.contributor.authorMustaffa, N-
dc.contributor.authorLimsrivilai, J-
dc.contributor.authorHisamatsu, T-
dc.contributor.authorYang, SK-
dc.contributor.authorOuyang, Q-
dc.contributor.authorGeary, R-
dc.contributor.authorDe Silva, JH-
dc.contributor.authorRerknimitr, R-
dc.contributor.authorSimadibrata, M-
dc.contributor.authorAbdullah, M-
dc.contributor.authorLeong, RWL-
dc.date.accessioned2020-09-22T02:56:39Z-
dc.date.available2020-09-22T02:56:39Z-
dc.date.issued2019-
dc.identifier.citationIntestinal Research, 2019, v. 17 n. 3, p. 285-310-
dc.identifier.issn1598-9100-
dc.identifier.urihttp://hdl.handle.net/10722/287157-
dc.descriptionOn behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis-
dc.description.abstractThe Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.-
dc.languageeng-
dc.publisherKorean Association for the Study of Intestinal Diseases. The Journal's web site is located at http://www.irjournal.org/-
dc.relation.ispartofIntestinal Research-
dc.rightsIntestinal Research. Copyright © Korean Association for the Study of Intestinal Diseases.-
dc.rightsCopyright © 2013 by Korean Association for the Study of Intestinal Disease. All Right Reserved.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectInflammatory bowel disease-
dc.subjectCrohn disease-
dc.subjectColitis-
dc.subjectulcerative-
dc.subjectInfliximab-
dc.titleBest practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia-
dc.typeArticle-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityLeung, WK=rp01479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.5217/ir.2019.00026-
dc.identifier.pmid31146509-
dc.identifier.pmcidPMC6667368-
dc.identifier.hkuros314433-
dc.identifier.volume17-
dc.identifier.issue3-
dc.identifier.spage285-
dc.identifier.epage310-
dc.identifier.isiWOS:000477572400002-
dc.publisher.placeRepublic of Korea-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats